Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timapiprant in Severe Refractory Eosinophilic Asthma
NCT02560610Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Sep 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of timapiprant in eosinophilic asthma (EA), sponsored by Chiesi Farmaceutici S.p.A.. Started Sep 2016; status: completed.
02
Drugs
timapiprant
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT02560610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02560610.